-
Je něco špatně v tomto záznamu ?
Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods
J. Závora, G. Kroneislová, M. Kroneisl, V. Adámková
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
MH CZ - DRO - VFN00064165
Ministry of Health, Czech Republic
NLK
Directory of Open Access Journals
od 2012
PubMed Central
od 2012
Europe PubMed Central
od 2012
ProQuest Central
od 2012-01-01
Open Access Digital Library
od 2012-01-01
Open Access Digital Library
od 2012-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2012
- Publikační typ
- časopisecké články MeSH
Background: Fosfomycin (FOS) is an older antimicrobial agent newly rediscovered as a possible treatment for infections with limited therapeutic options (e.g., Gram-negative bacteria with difficult-to-treat resistance, DTR), especially in intravenous form. However, for correct usage of FOS, it is necessary to have a reliable susceptibility testing method suitable for routine practice and robust interpretation criteria. Results: The results were interpreted according to 2023 interpretation criteria provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). DTR Gram-negatives were more likely to be resistant to FOS (45% in Enterobacterales and 20% in P. aeruginosa) than non-DTR (10% and 6.7%, resp.). All isolates of S. aureus were susceptible to FOS. In Gram-negatives, all agreement values were unacceptable. Etest® performed better in the DTR cohort (categorical agreement, CA, 80%) than in the non-DTR cohort (CA 45.7%). There were no very major errors (VREs) observed in P. aeruginosa. S. aureus had surprisingly low essential agreement (EA) rates (53% for MRSA and 47% for MSSA) for Etest®, but categorical agreement was 100%. Methods: A total of 130 bacterial isolates were tested and compared using the disc diffusion method (DD) and gradient strip method (Etest®) with the reference method (agar dilution, AD). The spectrum of isolates tested was as follows: 40 Enterobacterales (20 DTR vs. 20 non-DTR), 30 Pseudomonas aeruginosa (15 DTR vs. 15 non-DTR), and 60 Staphylococcus aureus (30 methicillin-susceptible, MSSA, vs. 30 methicillin-resistant, MRSA). Conclusions: Neither one of the tested methods was identified as a suitable alternative to AD. It would be beneficial to define more interpretation criteria, at least in some instances.
Clinical Microbiology and ATB Centre General University Hospital 128 08 Prague Czech Republic
Department of Medical Microbiology Palacky University 779 00 Olomouc Czech Republic
Department of Surgery University Hospital Bulovka 180 00 Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002200
- 003
- CZ-PrNML
- 005
- 20250123102021.0
- 007
- ta
- 008
- 250117s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/antibiotics13111049 $2 doi
- 035 __
- $a (PubMed)39596744
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Závora, Jan $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $u Department of Medical Microbiology, Palacky University, 779 00 Olomouc, Czech Republic $1 https://orcid.org/0000000262386514
- 245 10
- $a Fosfomycin-Overcoming Problematic In Vitro Susceptibility Testing and Tricky Result Interpretation: Comparison of Three Fosfomycin Susceptibility Testing Methods / $c J. Závora, G. Kroneislová, M. Kroneisl, V. Adámková
- 520 9_
- $a Background: Fosfomycin (FOS) is an older antimicrobial agent newly rediscovered as a possible treatment for infections with limited therapeutic options (e.g., Gram-negative bacteria with difficult-to-treat resistance, DTR), especially in intravenous form. However, for correct usage of FOS, it is necessary to have a reliable susceptibility testing method suitable for routine practice and robust interpretation criteria. Results: The results were interpreted according to 2023 interpretation criteria provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). DTR Gram-negatives were more likely to be resistant to FOS (45% in Enterobacterales and 20% in P. aeruginosa) than non-DTR (10% and 6.7%, resp.). All isolates of S. aureus were susceptible to FOS. In Gram-negatives, all agreement values were unacceptable. Etest® performed better in the DTR cohort (categorical agreement, CA, 80%) than in the non-DTR cohort (CA 45.7%). There were no very major errors (VREs) observed in P. aeruginosa. S. aureus had surprisingly low essential agreement (EA) rates (53% for MRSA and 47% for MSSA) for Etest®, but categorical agreement was 100%. Methods: A total of 130 bacterial isolates were tested and compared using the disc diffusion method (DD) and gradient strip method (Etest®) with the reference method (agar dilution, AD). The spectrum of isolates tested was as follows: 40 Enterobacterales (20 DTR vs. 20 non-DTR), 30 Pseudomonas aeruginosa (15 DTR vs. 15 non-DTR), and 60 Staphylococcus aureus (30 methicillin-susceptible, MSSA, vs. 30 methicillin-resistant, MRSA). Conclusions: Neither one of the tested methods was identified as a suitable alternative to AD. It would be beneficial to define more interpretation criteria, at least in some instances.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kroneislová, Gabriela $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $1 https://orcid.org/0009000536075498
- 700 1_
- $a Kroneisl, Marie $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 9700 Groningen, The Netherlands $u Department of Surgery, University Hospital Bulovka, 180 00 Prague, Czech Republic $1 https://orcid.org/0009000904091193
- 700 1_
- $a Adámková, Václava $u Clinical Microbiology and ATB Centre, General University Hospital, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000276295365 $7 xx0070151
- 773 0_
- $w MED00195446 $t Antibiotics (Basel) $x 2079-6382 $g Roč. 13, č. 11 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39596744 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250117 $b ABA008
- 991 __
- $a 20250123102015 $b ABA008
- 999 __
- $a ok $b bmc $g 2254498 $s 1238203
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 13 $c 11 $e 20241105 $i 2079-6382 $m Antibiotics (Basel) $n Antibiotics (Basel) $x MED00195446
- GRA __
- $a MH CZ - DRO - VFN00064165 $p Ministry of Health, Czech Republic
- LZP __
- $a Pubmed-20250117